600
Participants
Start Date
November 21, 2023
Primary Completion Date
December 26, 2029
Study Completion Date
December 26, 2029
Faricimab
6.0 mg intravitreal injection at randomization and every 3 months
fluocinolone acetonide
0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
RECRUITING
Retina-Vitreous Consultants, Inc., Monroeville
RECRUITING
Wills Eye Hospital, Philadelphia
RECRUITING
Retina Consultants of Carolina, PA, Greenville
RECRUITING
Retina Associates of Florida, LLC, Tampa
RECRUITING
Tennessee Retina, PC, Nashville
RECRUITING
The Cleveland Clinic Foundation DBA Cleveland Clinic Lerner College of Medicine, Cleveland
RECRUITING
Midwest Eye Institute, Indianapolis
RECRUITING
Associated Retinal Consultants, P.C., Royal Oak
RECRUITING
Foundation for Vision Research and Retina Specialists of Michigan, P.C., Grand Rapids
RECRUITING
University of Iowa Department of Ophthalmology and Visual Sciences, Iowa City
RECRUITING
The Board of Regents of the University of Wisconsin System, Madison
RECRUITING
Mayo Clinic, Rochester
RECRUITING
IL Eye and Ear Infirmary-University of Illinois at Chicago, Chicago
RECRUITING
Retina Research Institute, LLC, St Louis
RECRUITING
Retina Consultants of Texas, PA, Bellaire
RECRUITING
Texas Retina Associates, Lubbock
RECRUITING
Byers Eye Institute at Stanford University, Palo Alto
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Retina Consultants, Manchester
Lead Sponsor
Collaborators (2)
National Eye Institute (NEI)
NIH
National Institutes of Health (NIH)
NIH
Alimera Sciences
INDUSTRY
Genentech, Inc.
INDUSTRY
Jaeb Center for Health Research
OTHER